Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Noxopharm Ltd V.NOX


Primary Symbol: NOXOF

Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA vaccine enhancement). Chroma is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment. The Sofra technology platform has a pipeline of proprietary drugs based on oligonucleotides, the building blocks of deoxyribonucleic acid (DNA), with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-VAC has applications in the treatment of excessive inflammatory responses associated with specialized inflammatory receptors in the body known as Toll-like receptor 7.


OTCPK:NOXOF - Post by User

Comment by mullatschakon Feb 05, 2013 12:53pm
206 Views
Post# 20940999

RE: RE: Re: Financing

RE: RE: Re: Financing

Flow through financings are the best possibilities for Juniors to finance the biz.

 

Why?

 

It allows the Investor Tax efforts of appr. 25%. This means, you have to deduct 25% of 0,52 CAD, then you know what premium the investors really paid. It is about 0,41 CAD. Sounds also good, but is something else then 0,52 CAD.

I'm not sure, who participated in the financing. Hope that Wexford is not the related party. If these guys are around, there is nothing to win for small investors. On my best knowledge Wexford is one of the bigger shareholders in Nox. This is not my favourite constellation, and it is the only thing, what tells me, not to invest too much into this company. But the business model is very good. If it pays really out for us one day, it will be one of my better investments.

 

<< Previous
Bullboard Posts
Next >>